HAMBURG, Germany and OXFORD, England, September 19 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today that David Brister has been appointed Chief Business Officer and a member of the Company’s Executive Committee. In this newly created role he will coordinate the business development activities of both Evotec’s Pharmaceuticals and Services Divisions, reinforcing the customer focused approach and strategic account management. David will focus on negotiations of partnerships and licensing agreements as well as on the implementation of Evotec’s M&A strategy. He will report to Joern Aldag, President and Chief Executive Officer.
